{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:56:05Z","timestamp":1793465765625,"version":"4.5.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.joca.2021.11.017","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T02:37:02Z","timestamp":1638412622000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Expanding horizons of achondroplasia treatment: current options and future developments"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-7937","authenticated-orcid":false,"given":"B.","family":"Fafilek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-0344","authenticated-orcid":false,"given":"M.","family":"Bosakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Krejci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2021.11.017_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ng0496-390","article-title":"Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3","volume":"12","author":"Colvin","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0092-8674(00)81069-7","article-title":"Fibroblast growth factor receptor 3 is a negative regulator of bone growth","volume":"84","author":"Deng","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.joca.2021.11.017_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/508433","article-title":"A\u00a0novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome","volume":"79","author":"Toydemir","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2021.11.017_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2021.11.017_bib6","first-page":"123","article-title":"Growth hormone treatment for achondroplasia","volume":"16","author":"Yorifuji","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.joca.2021.11.017_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-3-reviews3005","article-title":"Fibroblast growth factors","volume":"2","author":"Ornitz","year":"2001","journal-title":"Genome Biol"},{"key":"10.1016\/j.joca.2021.11.017_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.joca.2021.11.017_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.molcel.2006.01.022","article-title":"Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction","volume":"21","author":"Furdui","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.joca.2021.11.017_bib10","doi-asserted-by":"crossref","first-page":"D165","DOI":"10.2741\/Klint","article-title":"Signal transduction by fibroblast growth factor receptors","volume":"4","author":"Klint","year":"1999","journal-title":"Front Biosci"},{"key":"10.1016\/j.joca.2021.11.017_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1074\/mcp.RA117.000538","article-title":"Protein tyrosine phosphatase receptor type G (PTPRG) controls fibroblast growth factor receptor (FGFR) 1 activity and influences sensitivity to FGFR kinase inhibitors","volume":"17","author":"Kostas","year":"2018","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.joca.2021.11.017_bib12","first-page":"11","article-title":"The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases","author":"Fafilek","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.joca.2021.11.017_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yexcr.2004.03.011","article-title":"FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells","volume":"297","author":"Krejci","year":"2004","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.joca.2021.11.017_bib14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1074\/jbc.M310384200","article-title":"Activation of the ERK1\/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes","volume":"279","author":"Raucci","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jor.21262","article-title":"Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal","volume":"29","author":"Sebastian","year":"2011","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.joca.2021.11.017_bib16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/jcp.20620","article-title":"Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes","volume":"207","author":"Priore","year":"2006","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.joca.2021.11.017_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/386288a0","article-title":"Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism","volume":"386","author":"Su","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.joca.2021.11.017_bib18","first-page":"839","article-title":"Fibroblast growth factor and canonical WNT\/\u03b2-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage","volume":"2015","author":"Buchtova","year":"1852","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.joca.2021.11.017_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biocel.2017.12.008","article-title":"Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLC\u03b31\/Src-mediated paxillin hyperphosphorylation","volume":"95","author":"Montone","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.joca.2021.11.017_bib20","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1080\/15548627.2015.1091551","article-title":"FGFR3\/fibroblast growth factor receptor 3 inhibits autophagy through decreasing the ATG12-ATG5 conjugate, leading to the delay of cartilage development in achondroplasia","volume":"11","author":"Wang","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.joca.2021.11.017_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cellsig.2008.10.006","article-title":"Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes","volume":"21","author":"Krejci","year":"2009","journal-title":"Cell Signal"},{"key":"10.1016\/j.joca.2021.11.017_bib22","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/hmg\/ddu594","article-title":"Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes","volume":"24","author":"Zhou","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib23","first-page":"1237","article-title":"FGFR3 induces degradation of BMP type I receptor to regulate skeletal development","volume":"2014","author":"Qi","year":"1843","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.joca.2021.11.017_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jmicro\/dfq002","article-title":"FGFR3 down-regulates PTH\/PTHrP receptor gene expression by mediating JAK\/STAT signaling in chondrocytic cell line","volume":"59","author":"Li","year":"2010","journal-title":"J\u00a0Electron Microsc (Tokyo)"},{"key":"10.1016\/j.joca.2021.11.017_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/hmg\/10.5.457","article-title":"A\u00a0Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh\/PTHrP signals and causes severe achondroplasia","volume":"10","author":"Chen","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/hmg\/ddy031","article-title":"Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies","volume":"27","author":"Kunova Bosakova","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddx374","article-title":"Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia","volume":"27","author":"Martin","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1359\/jbmr.2003.18.8.1395","article-title":"PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation","volume":"18","author":"Yamanaka","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.joca.2021.11.017_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.joca.2021.11.017_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ymgme.2007.06.014","article-title":"C-natriuretic peptide: an important regulator of cartilage","volume":"92","author":"Pejchalova","year":"2007","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.joca.2021.11.017_bib31","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1073\/pnas.071389098","article-title":"Dwarfism and early death in mice lacking C-type natriuretic peptide","volume":"98","author":"Chusho","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2021.11.017_bib32","doi-asserted-by":"crossref","first-page":"17300","DOI":"10.1073\/pnas.0407894101","article-title":"Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs","volume":"101","author":"Tamura","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2021.11.017_bib33","doi-asserted-by":"crossref","first-page":"7403","DOI":"10.1073\/pnas.96.13.7403","article-title":"The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system","volume":"96","author":"Matsukawa","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2021.11.017_bib34","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1126\/science.274.5295.2082","article-title":"Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II","volume":"274","author":"Pfeifer","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.joca.2021.11.017_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00774-004-0598-8","article-title":"Mutation in cGMP-dependent protein kinase II causes dwarfism in a rat mutant KMI through uncoupling of proliferation and differentiation of chondrocytes","volume":"23","author":"Chikuda","year":"2005","journal-title":"J\u00a0Bone Miner Metabol"},{"key":"10.1016\/j.joca.2021.11.017_bib36","doi-asserted-by":"crossref","first-page":"10278","DOI":"10.1073\/pnas.96.18.10278","article-title":"Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3)","volume":"96","author":"Jaubert","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2021.11.017_bib37","doi-asserted-by":"crossref","first-page":"E1339","DOI":"10.1152\/ajpendo.00272.2009","article-title":"Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice","volume":"297","author":"Kake","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.joca.2021.11.017_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/422013","article-title":"Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux","volume":"75","author":"Bartels","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/gim.2017.66","article-title":"Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature","volume":"20","author":"Hisado-Oliva","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.joca.2021.11.017_bib40","doi-asserted-by":"crossref","first-page":"E1636","DOI":"10.1210\/jc.2013-2142","article-title":"Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature","volume":"98","author":"Vasques","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.joca.2021.11.017_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/humu.22773","article-title":"Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature","volume":"36","author":"Wang","year":"2015","journal-title":"Hum Mutat"},{"key":"10.1016\/j.joca.2021.11.017_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ajhg.2018.06.007","article-title":"Bi-allelic loss-of-function mutations in the NPR-C receptor result in enhanced growth and connective tissue abnormalities","volume":"103","author":"Boudin","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Yasoda","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.joca.2021.11.017_bib44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbrc.2017.01.001","article-title":"Type II cGMP-dependent protein kinase negatively regulates fibroblast growth factor signaling by phosphorylating Raf-1 at serine 43 in rat chondrosarcoma cells","volume":"483","author":"Kamemura","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.joca.2021.11.017_bib45","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1242\/jcs.02618","article-title":"Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis","volume":"118","author":"Krejci","year":"2005","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.joca.2021.11.017_bib46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bone.2005.03.006","article-title":"Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells","volume":"36","author":"Ozasa","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.joca.2021.11.017_bib47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.joca.2021.11.017_bib48","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.joca.2021.11.017_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212680","article-title":"ASB20123: a novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism","volume":"14","author":"Morozumi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218229","article-title":"Safety assessment of a novel C-type natriuretic peptide derivative and the mechanism of bone- and cartilage-specific toxicity","volume":"14","author":"Yotsumoto","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib52","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/bcp.14257","article-title":"The effects of meclizine on motion sickness revisited","volume":"86","author":"Wibble","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.joca.2021.11.017_bib53","doi-asserted-by":"crossref","first-page":"e81569","DOI":"10.1371\/journal.pone.0081569","article-title":"Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib54","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/en.2014-1914","article-title":"Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene","volume":"156","author":"Matsushita","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.joca.2021.11.017_bib55","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1038\/s41598-017-07044-8","article-title":"Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia","volume":"7","author":"Matsushita","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.joca.2021.11.017_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229639","article-title":"Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia","volume":"15","author":"Kitoh","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1098-1004(1999)14:2<115::AID-HUMU3>3.0.CO;2-2","article-title":"Clinical spectrum of fibroblast growth factor receptor mutations","volume":"14","author":"Passos-Bueno","year":"1999","journal-title":"Hum Mutat"},{"key":"10.1016\/j.joca.2021.11.017_bib58","doi-asserted-by":"crossref","first-page":"30103","DOI":"10.1074\/jbc.M109.094086","article-title":"Physical basis behind achondroplasia, the most common form of human dwarfism","volume":"285","author":"He","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.omtn.2019.07.018","article-title":"Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease","volume":"17","author":"Matsuda","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.joca.2021.11.017_bib60","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1038\/s41598-021-82350-w","article-title":"Specific inhibition of FGF5-induced cell proliferation by RNA aptamers","volume":"11","author":"Amano","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.joca.2021.11.017_bib61","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/jacsau.0c00121","article-title":"A\u00a0DNA aptamer that inhibits the aberrant signaling of fibroblast growth factor receptor in cancer cells","volume":"1","author":"Eguchi","year":"2021","journal-title":"Jacs Au"},{"key":"10.1016\/j.joca.2021.11.017_bib62","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtn.2019.06.020","article-title":"Development of a monomeric inhibitory RNA aptamer specific for FGFR3 that acts as an activator when dimerized","volume":"17","author":"Kamatkar","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.joca.2021.11.017_bib63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1203\/pdr.0b013e318030d157","article-title":"Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage","volume":"61","author":"Krejci","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1016\/j.joca.2021.11.017_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4226","article-title":"An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice","volume":"13","author":"Kimura","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.joca.2021.11.017_bib65","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ydbio.2006.08.071","article-title":"FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate","volume":"302","author":"Liu","year":"2007","journal-title":"Dev Biol"},{"key":"10.1016\/j.joca.2021.11.017_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/humu.21636","article-title":"Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias","volume":"33","author":"Foldynova-Trantirkova","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.joca.2021.11.017_bib68","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1021\/jm970367n","article-title":"Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors","volume":"40","author":"Hamby","year":"1997","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib69","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1126\/science.276.5314.955","article-title":"Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors","volume":"276","author":"Mohammadi","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.joca.2021.11.017_bib70","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/onc.2012.319","article-title":"Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance","volume":"32","author":"Chell","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.joca.2021.11.017_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): Structures and Small Molecule Inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.joca.2021.11.017_bib72","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.joca.2021.11.017_bib73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-16-0188","article-title":"ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma","volume":"16","author":"Futami","year":"2017","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.joca.2021.11.017_bib74","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.joca.2021.11.017_bib75","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-16-0261","article-title":"E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models","volume":"15","author":"Watanabe Miyano","year":"2016","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.joca.2021.11.017_bib76","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.joca.2021.11.017_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation","volume":"11","author":"Hall","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib78","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284\/Debio 1347, a novel selective FGFR inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.joca.2021.11.017_bib79","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-10-2700","article-title":"E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models","volume":"71","author":"Bello","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.joca.2021.11.017_bib80","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joca.2021.11.017_bib81","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.joca.2021.11.017_bib82","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ijc.32224","article-title":"Rogaratinib: a potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models","volume":"145","author":"Gr\u00fcnewald","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.joca.2021.11.017_bib83","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joca.2021.11.017_bib84","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A\u00a0novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.joca.2021.11.017_bib85","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/hmg\/ddr514","article-title":"A\u00a0novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model","volume":"21","author":"Jonquoy","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib86","doi-asserted-by":"crossref","first-page":"20915","DOI":"10.1038\/s41598-020-77345-y","article-title":"Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia","volume":"10","author":"Ozaki","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.joca.2021.11.017_bib87","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2017.08.016","article-title":"ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3","volume":"105","author":"Balek","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.joca.2021.11.017_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/hmg\/ddv441","article-title":"Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes","volume":"25","author":"Gudernova","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2015.07.002","article-title":"Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy","volume":"28","author":"Ronca","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.joca.2021.11.017_bib90","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A\u00a0phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joca.2021.11.017_bib91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biomaterials.2018.05.030","article-title":"Nanodiamonds as \"artificial proteins\": regulation of a cell signalling system using low nanomolar solutions of inorganic nanocrystals","volume":"176","author":"Balek","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.joca.2021.11.017_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006247","article-title":"Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice","volume":"5","author":"Garcia","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.joca.2021.11.017_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195876","article-title":"Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia","volume":"13","author":"Saint-Laurent","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244368","article-title":"In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia","volume":"15","author":"Gon\u00e7alves","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.joca.2021.11.017_bib95","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/ard.2003.009746","article-title":"Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture","volume":"63","author":"Lazzerini","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2021.11.017_bib96","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jor.20953","article-title":"Protective effect of atorvastatin in cultured osteoarthritic chondrocytes","volume":"28","author":"Simopoulou","year":"2010","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.joca.2021.11.017_bib97","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature13775","article-title":"Statin treatment rescues FGFR3 skeletal dysplasia phenotypes","volume":"513","author":"Yamashita","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.joca.2021.11.017_bib98","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.joca.2017.05.014","article-title":"Statins do not inhibit the FGFR signaling in chondrocytes","volume":"25","author":"Fafilek","year":"2017","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2021.11.017_bib99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.joca.2015.01.002","article-title":"A\u00a0new prescription for growth? Statins, cholesterol and cartilage homeostasis","volume":"23","author":"Bush","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2021.11.017_bib100","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1074\/jbc.M305518200","article-title":"Role of cholesterol in the regulation of growth plate chondrogenesis and longitudinal bone growth","volume":"279","author":"Wu","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib101","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1111\/j.1582-4934.2008.00684.x","article-title":"Control of chondrocyte gene expression by actin dynamics: a novel role of cholesterol\/Ror-alpha signalling in endochondral bone growth","volume":"13","author":"Woods","year":"2009","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.joca.2021.11.017_bib102","article-title":"The effects of fluvastatin on Indian hedgehog pathway in endochondral ossification","author":"Ishikawa","year":"2019","journal-title":"Cartilage"},{"key":"10.1016\/j.joca.2021.11.017_bib103","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1073\/pnas.1800338116","article-title":"Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase","volume":"116","author":"Kunova Bosakova","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2021.11.017_bib104","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.joca.2021.11.017_bib105","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"Qing","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.joca.2021.11.017_bib106","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00280-011-1807-5","article-title":"Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma","volume":"69","author":"Kamath","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.joca.2021.11.017_bib107","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1007\/s00253-014-5541-x","article-title":"High-level expression, purification, and characterization of bifunctional ScFv-9R fusion protein","volume":"98","author":"Zhang","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.joca.2021.11.017_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126240","article-title":"Semi-automated cell panning for efficient isolation of FGFR3-targeting antibody","volume":"22","author":"Min","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.joca.2021.11.017_bib109","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1101\/gad.8.3.277","article-title":"Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene","volume":"8","author":"Karaplis","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.joca.2021.11.017_bib110","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1073\/pnas.89.7.2732","volume":"89","author":"Abou-Samra","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.joca.2021.11.017_bib111","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1242\/dev.128.4.541","article-title":"The CREB family of activators is required for endochondral bone development","volume":"128","author":"Long","year":"2001","journal-title":"Development"},{"key":"10.1016\/j.joca.2021.11.017_bib112","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.joca.2021.11.017_bib113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1186\/s12864-017-4378-y","article-title":"Genes uniquely expressed in human growth plate chondrocytes uncover a distinct regulatory network","volume":"18","author":"Li","year":"2017","journal-title":"BMC Genom"},{"key":"10.1016\/j.joca.2021.11.017_bib114","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1093\/nar\/gkv688","article-title":"The transcription factors SOX9 and SOX5\/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis","volume":"43","author":"Liu","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.joca.2021.11.017_bib115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2350-6-9","article-title":"Association between a variation in the phosphodiesterase 4D gene and bone mineral density","volume":"6","author":"Reneland","year":"2005","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib116","series-title":"Bone-metabolic Functions and Modulators","first-page":"1","author":"Bronner","year":"2012"},{"key":"10.1016\/j.joca.2021.11.017_bib117","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S8756-3282(00)00395-1","article-title":"Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice","volume":"27","author":"Kinoshita","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.joca.2021.11.017_bib118","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/002215549704500710","article-title":"Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues","volume":"45","author":"Hughes","year":"1997","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.joca.2021.11.017_bib119","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.joca.2021.11.017_bib120","doi-asserted-by":"crossref","first-page":"11620","DOI":"10.1016\/S0021-9258(19)78170-8","article-title":"Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF\/FGF-1","volume":"269","author":"Chellaiah","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib121","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1242\/dev.00184","article-title":"Fgfr3 expression by astrocytes and their precursors: evidence that astrocytes and oligodendrocytes originate in distinct neuroepithelial domains","volume":"130","author":"Pringle","year":"2003","journal-title":"Development"},{"key":"10.1016\/j.joca.2021.11.017_bib122","doi-asserted-by":"crossref","first-page":"G168","DOI":"10.1152\/ajpgi.90589.2008","article-title":"Fibroblast growth factor receptor-3 regulates Paneth cell lineage allocation and accrual of epithelial stem cells during murine intestinal development","volume":"297","author":"Vidrich","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.joca.2021.11.017_bib123","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/dbio.1993.1040","article-title":"Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis","volume":"155","author":"Peters","year":"1993","journal-title":"Dev Biol"},{"key":"10.1016\/j.joca.2021.11.017_bib124","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1097\/00003086-199910001-00018","article-title":"Fibroblast growth factor receptor-3 as a marker for precartilaginous stem cells","author":"Robinson","year":"1999","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.joca.2021.11.017_bib125","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/hmg\/ddp590","article-title":"Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis","volume":"19","author":"Su","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib126","doi-asserted-by":"crossref","first-page":"27743","DOI":"10.1074\/jbc.M314323200","article-title":"Stat1 controls postnatal bone formation by regulating fibroblast growth factor signaling in osteoblasts","volume":"279","author":"Xiao","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2021.11.017_bib127","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jbmr.2839","article-title":"Deletion of FGFR3 in osteoclast lineage cells results in increased bone mass in mice by inhibiting osteoclastic bone resorption","volume":"31","author":"Su","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.joca.2021.11.017_bib128","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/nbt.3295","article-title":"High-throughput sequencing of DNA G-quadruplex structures in the human genome","volume":"33","author":"Chambers","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.joca.2021.11.017_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040841","article-title":"Recent developments in small-molecule ligands of medicinal relevance for harnessing the anticancer potential of G-quadruplexes","volume":"26","author":"Savva","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.joca.2021.11.017_bib130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cellsig.2017.09.021","article-title":"Dephosphorylation is the mechanism of fibroblast growth factor inhibition of guanylyl cyclase-B","volume":"40","author":"Robinson","year":"2017","journal-title":"Cell Signal"},{"key":"10.1016\/j.joca.2021.11.017_bib131","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31343","article-title":"Dephosphorylation of the NPR2 guanylyl cyclase contributes to inhibition of bone growth by fibroblast growth factor","volume":"6","author":"Shuhaibar","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.joca.2021.11.017_bib132","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147832","article-title":"Prevention of guanylyl cyclase-B dephosphorylation rescues achondroplastic dwarfism","volume":"6","author":"Wagner","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.joca.2021.11.017_bib133","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141426","article-title":"Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth","volume":"6","author":"Shuhaibar","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.joca.2021.11.017_bib134","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1210\/jc.2014-2814","article-title":"C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia","volume":"100","author":"Olney","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.joca.2021.11.017_bib135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrendo.2015.165","article-title":"Short and tall stature: a new paradigm emerges","volume":"11","author":"Baron","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.joca.2021.11.017_bib136","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/archpedi.156.3.230","article-title":"Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis","volume":"156","author":"Finkelstein","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.joca.2021.11.017_bib137","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2265.2011.04230.x","article-title":"Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature","volume":"77","author":"Hughes","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.joca.2021.11.017_bib138","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMc1910394","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Krejci","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2021.11.017_bib139","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ebiom.2019.01.010","article-title":"Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias","volume":"40","author":"Zheng","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.joca.2021.11.017_bib140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/hmg\/ddy333","article-title":"C-type natriuretic peptide improves growth retardation in a mouse model of cardio-facio-cutaneous syndrome","volume":"28","author":"Inoue","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.joca.2021.11.017_bib141","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1038\/s41598-019-44975-w","article-title":"Exogenous C-type natriuretic peptide therapy for impaired skeletal growth in a murine model of glucocorticoid treatment","volume":"9","author":"Ueda","year":"2019","journal-title":"Sci Rep"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458421009808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458421009808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:56:37Z","timestamp":1761018997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458421009808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1063458421009808"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2021.11.017","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding horizons of achondroplasia treatment: current options and future developments","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2021.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Osteoarthritis Research Society International. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}